TY - JOUR
T1 - Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia
AU - GENFI Consortium
AU - Benussi, Alberto
AU - Alberici, Antonella
AU - Samra, Kiran
AU - Russell, Lucy L.
AU - Greaves, Caroline V.
AU - Bocchetta, Martina
AU - Ducharme, Simon
AU - Finger, Elizabeth
AU - Fumagalli, Giorgio
AU - Galimberti, Daniela
AU - Jiskoot, Lize C.
AU - Le Ber, Isabelle
AU - Masellis, Mario
AU - Nacmias, Benedetta
AU - Rowe, James B.
AU - Sanchez-Valle, Raquel
AU - Seelaar, Harro
AU - Synofzik, Matthis
AU - Rohrer, Jonathan D.
AU - Borroni, Barbara
AU - Afonso, Sónia
AU - Almeida, Maria Rosario
AU - Anderl-Straub, Sarah
AU - Andersson, Christin
AU - Antonell, Anna
AU - Archetti, Silvana
AU - Arighi, Andrea
AU - Balasa, Mircea
AU - Barandiaran, Myriam
AU - Bargalló, Nuria
AU - Bartha, Robart
AU - Bender, Benjamin
AU - Bertoux, Maxime
AU - Bertrand, Anne
AU - Bessi, Valentina
AU - Black, Sandra
AU - Borrego-Ecija, Sergi
AU - Bouzigues, Arabella
AU - Bras, Jose
AU - Brice, Alexis
AU - Bruffaerts, Rose
AU - Butler, Chris R.
AU - Camuzat, Agnès
AU - Cañada, Marta
AU - Cantoni, Valentina
AU - Caroppo, Paola
AU - Cash, David
AU - Castelo-Branco, Miguel
AU - Colliot, Olivier
AU - Maruta, Carolina
N1 - Funding Information:
Alberto Benussi was partially supported by the Airalzh‐AGYR2020 grant and participated as Data Safety Monitoring Board member (Beth Israel Deaconess Medical Center, USA). Lucy L. Russell received support by Guarantors of Brain and Alzheimer's Research UK for attending a meeting. Caroline V. Greaves received support by Guarantors of Brain travel award institution (ARUK travel award) for attending a meeting. Martina Bocchetta was partially supported by a Fellowship award from the Alzheimer's Society, UK (AS‐JF‐19a‐004‐517) and was partially supported by the UK Dementia Research Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. Simon Ducharme was partially supported by Biogen, Ionis, and AZ Therapies; received personal fees from Eisai and Innodem Neurosciences; and received speaker honoraria from Sunovion and Eisai. Elizabeth Finger was partially supported by Cihr operating grant, Weston Foundation, and PSI and received personal fees from Vigil Neuro and Biogen. Isabelle Le Ber was partially supported by Investissements d'avenir ANR‐11‐INBS‐0011, PHRC FTLD‐exome (promotion by Assistance Publique – Hôpitaux de Paris), PHRC Predict‐PGRN, ANR‐PRTS PRTS (ANR‐14‐CE15‐0016‐07, promotion by Assistance Publique – Hôpitaux de Paris), and JPND STRATALS; received personal fees from Prevail Therapeutic and Alector Pharmaceuticals; and received honoraria for educational course of the Movement Disorder Society. Mario Masellis was partially supported by Canadian Institutes of Health Research, Ontario Brain Institute, Weston Brain Institute, Washington University, Alector Pharmaceuticals, and Novartis; and received personal fees from Royalties, Henry Stewart Talks, Arkuda Therapeutics, Ionis Pharmaceuticals, Alector Pharmaceuticals, Wave Life Sciences, and Biogen Canada. James B. Rowe was partially supported by the University of Cambridge, Medical Research Council (SUAG/051 G101400), NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014; the views expressed are those of the author and not necessarily those of the NIHR or the Department of Health and Social Care; Holt Fellowship; the Wellcome Trust [103838]), Janssen, Lily, AZ‐Medimmune, Wellcome Trust, Evelyn Trust, Alzheimer Research UK, and PSP Association; applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission for the purpose of open access; received personal fees from Asceneuron, Biogen, WAV, SV Health, Astex and UCB, SAB Asceneuron; and received personal payments for work as expert witness in personal civil cases; participated at Trustee, PSP Association Trustee, Guarantors of Brain Trustee, Darwin College board (all unpaid). Raquel Sanchez‐Valle was partially supported by Instituto de Salud Carlos III, Spain, grant number PI20/00448 and Sage Pharmaceuticals; received personal fees from Ionnis and Wave Pharmaceuticals; received honoraria for participation in educational events from Roche, Janssen, and Neuraxpharm; and participated on a Data Safety Monitoring Board from Wave Pharmaceuticals. Matthis Synofzik was partially supported by DLR/BMBF, DFG, and EJPRD grants; received consultancy honoraria from Orphazyme Pharmaceuticals, Janssen Pharmaceuticals, and Ionis Pharmaceuticals; received speaker's honoraria from the Movement Disorders Society, unrelated to the present work; and served on an advisory board for Orphazyme Pharmaceuticals, unrelated to the present work. Jonathan D. Rohrer was partially supported by Bluefield Project, Joint Programme for NeuroDegeneration, Arkuda Therapeutics, and UCB; and received personal fees from Alector, Prevail Therapeutics, Wave Life Sciences. Barbara Borroni was partially supported by ADDF, unrelated to the present work; received personal fees from Alector and Wave Life Sciences; and is listed as an inventor on pending patent on the use of noninvasive brain stimulation to increase cognitive functions in patients with neurodegenerative disorders. Antonella Alberici, Kiran Samra, Giorgio Fumagalli, Daniela Galimberti, Lize C Jiskoot, Benedetta Nacmias, and Harro Seelaar report no disclosures.
Funding Information:
This project received support from the JPND grant “GENFI‐prox” to M.S, J.D.R., and B.B. M.B. is supported by a Fellowship award from the Alzheimer's Society, UK (AS‐JF‐19a‐004‐517). M.B.’s work is also supported by the UK Dementia Research Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. J.D.R. is supported by an MRC Clinician Scientist Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH).
Publisher Copyright:
© 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - The presymptomatic stages of frontotemporal dementia (FTD) are still poorly defined and encompass a long accrual of progressive biological (preclinical) and then clinical (prodromal) changes, antedating the onset of dementia. The heterogeneity of clinical presentations and the different neuropathological phenotypes have prevented a prior clear description of either preclinical or prodromal FTD. Recent advances in therapeutic approaches, at least in monogenic disease, demand a proper definition of these predementia stages. It has become clear that a consensus lexicon is needed to comprehensively describe the stages that anticipate dementia. The goal of the present work is to review existing literature on the preclinical and prodromal phases of FTD, providing recommendations to address the unmet questions, therefore laying out a strategy for operationalizing and better characterizing these presymptomatic disease stages.
AB - The presymptomatic stages of frontotemporal dementia (FTD) are still poorly defined and encompass a long accrual of progressive biological (preclinical) and then clinical (prodromal) changes, antedating the onset of dementia. The heterogeneity of clinical presentations and the different neuropathological phenotypes have prevented a prior clear description of either preclinical or prodromal FTD. Recent advances in therapeutic approaches, at least in monogenic disease, demand a proper definition of these predementia stages. It has become clear that a consensus lexicon is needed to comprehensively describe the stages that anticipate dementia. The goal of the present work is to review existing literature on the preclinical and prodromal phases of FTD, providing recommendations to address the unmet questions, therefore laying out a strategy for operationalizing and better characterizing these presymptomatic disease stages.
KW - Definition
KW - Frontotemporal dementia
KW - Frontotemporal lobar degeneration
KW - Mild cognitive and/or behavioral and/or motor impairment
KW - Mild cognitive impairment
KW - Preclinical
KW - Presymptomatic
KW - Prodromal
UR - http://www.scopus.com/inward/record.url?scp=85119071353&partnerID=8YFLogxK
U2 - 10.1002/alz.12485
DO - 10.1002/alz.12485
M3 - Article
C2 - 34874596
AN - SCOPUS:85119071353
SN - 1552-5260
VL - 18
SP - 1408
EP - 1423
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 7
ER -